Why the MDGs need good governance in pharmaceutical systems to promote global health

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Kohler, Jillian Clare ^a   MacKey, Tim Ken ^b   Ovtcharenko, Natalia ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b University of California at San Diego   (United States)

Author keywords

Access to medicines; Corruption; Global institutions; Good governance; Health systems; Pharmaceutical systems

Indexed keywords

DRUG;

ARTICLE; DRUG INDUSTRY; HEALTH; HEALTH CARE DELIVERY; HEALTH PROMOTION; HUMAN; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHARMACY; STANDARD; UNITED NATIONS;

DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HEALTHY PEOPLE PROGRAMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; UNITED NATIONS; WORLD HEALTH;

EID: 84892575978     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-63     Document Type: Review

References (28)

1. World Bank takes further step in anti-corruption fight: bank initiates annual report detailing investigations. http://web.worldbank.org/WBSITE/ EXTERNAL/NEWS/0,contentMDK:20368613enuPK:34463pagePK:64003015iPK: 64003012theSitePK:4607,00.html
2. A New global partnership: eradicate poverty and transform economies through sustainable development. http://www.un.org/sg/management/pdf/HLP-P2015- Report.pdf
3. Fighting corruption in the health sector: methods, tools and good practices. http://www.undp.org.tt/News/UNODC/ Anticorruption%20Methods%20and%20Tools%20in%20Health%20Lo%20Res%20final.pdf
4. Combating healthcare corruption and fraud with improved global health governance. Mackey TK, Liang BA, BMC Int Health Hum Rights 2012 12 23 10.1186/1472-698X-12-23 23088820
5. Off label promotion reform: a legislative proposal for addressing vulnerable patient drug access and limiting inappropriate pharmaceutical marketing. Mackey TK, Liang BA, Univ Michigan J Law Reform 2011 45 1
6. Johnson & Johnson reaches.2 billion Risperdal settlement. http://digitaljournal.com/article/361538#ixzz2mXVb7ztJ
7. What is good governance? http://www.unescap.org/pdd/prs/ ProjectActivities/Ongoing/gg/governance.asp
8. Helping countries combat corruption: the role of the World Bank. http://www1.worldbank.org/publicsector/anticorrupt/corruptn/cor02.htm#note1
9. Corruption and the provision of health care and education services. http://www.imf.org/external/pubs/ft/wp/2000/wp00116.pdf
10. Wages, capture, and penalties in Venezuela's public hospitals. Jaén M, Paravisini D, et al. Diagnosis Corruption: Fraud in Latin America's Public Hospitals Washington DC: Latin American Research Network, Inter-American Development Bank, Di Tella R, Savedoff W, 2001
11. Shining light in dark corners. Di Tella R, Savedoff W, Diagnosis Corruption: Fraud in Latin America's Public Hospitals Washington DC: Latin American Research Network, Inter-American Development Bank, Di Tella R, Savedoff W, 2001
12. Ferrinho P, Van Lerberghe W, Managing health professionals in the context of limited resources: a fine line between corruption and the need for moonlighting Washington, DC: World Bank Publications 2002
13. Pregnant women in Burkina Faso dying because of discrimination. http://www.amnesty.org/en/news-and-updates/report/pregnant-women-burkina-faso- dying-because-discrimination-20100127
14. Rebalancing brain drain: exploring resource reallocation to address health worker migration and promote global health. Mackey TK, Liang BA, Health Policy 2012 107 1 10.1016/j.healthpol.2012.05.001 22682763
15. The anti-corruption catalyst: realising the MDGs by 2015. http://www.transparency-usa.org/documents/ AntiCorruptionCatalystRealisingtheMDGby2015.pdf
16. Transparency and accountability in Argentina's hospitals. Schargrodsky E, Mera J, Weinschelbaum F, Diagnosis Corruption: Fraud in Latin America's Public Hospitals Washington DC: Latin American Research Network, Inter-American Development Bank, Di Tella R, Savedoff W, 2001
17. A United Nations global health panel for global health governance. Mackey TK, Liang BA, Soc Sci Med 2012 76 1 23026073
18. The global counterfeit drug trade: patient safety and public health risks. Mackey TK, Liang BA, J Pharm Sci 2011 100 4571 4579 10.1002/jps.22679 21698604
19. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction. Cohen JC, Mrazek M, Hawkins L, Clin Pharmacol Ther 2007 81 445 449 10.1038/sj.clpt.6100074 17251983 (Pubitemid 46364483)
20. The global use of medicines: outlook through 2016. http://www.imshealth. com/deployedfiles/ims/Global/Content/Insights/ IMS%20Institute%20for%20Healthcare%20Informatics/ Global%20Use%20of%20Meds%202011/Medicines-Outlook-Through-2016-Report.pdf
21. Good governance for medicines initiatives: exploring lessons learned. Kohler JC, Ovtcharenko N, U4 Anti-Corrupt Resour Centre 2013 3 1 26
22. Using technology to fight corruption in pharmaceutical purchasing: lessons from the Chilean experience. Cohen J, Montoya J, World Bank Institute 2001
23. Fiscal year 2008 annual integrity report: protecting Development's potential. http://siteresources.worldbank.org/INTDOII/Resources/INT- AnnualReport-web.pdf
24. WHO Good Governance for Medicines programme: an innovative approach to prevent corruption in the pharmaceutical sector. http://www.who.int/ healthsystems/topics/financing/healthreport/25GGM.pdf
25. Medicines transparency alliance: implementing our pilot phase. http://www.medicinestransparency.org/uploads/media/MeTA-Implementing-pilot- phase-01.pdf
26. The global fund to fight AIDS, tuberculosis and malaria annual report 2002/2003. http://www.theglobalfund.org/en/library/publications/annualreports/
27. Breakthrough on procurement to save $140 million. http://www.theglobalfund.org/en/mediacenter/newsreleases/2013-11-05- Breakthrough-on-Procurement-to-Save-USD-140-Million/
28. The global fund strategy 2012-2016: investing for impact. http://www.theglobalfund.org/en/about/strategy/